

# EXECUTIVE SUMMARY

First nine months 2025



## Main figures €Mn


|                    |                     |                     |
|--------------------|---------------------|---------------------|
| <b>Op. Revenue</b> | <b>EBITDA</b>       | <b>EBIT</b>         |
| <b>525.1 (-7%)</b> | <b>149.5 (-11%)</b> | <b>127.3 (-13%)</b> |
| <b>Net profit</b>  | <b>Capex</b>        | <b>Net debt</b>     |
| <b>97.7 (-14%)</b> | <b>38.5 (+14%)</b>  | <b>72.4</b>         |

**2026 operating revenue growth rate:**  
Increase by between a high single-digit and low double-digit percentage vs 2025


- ✓ ROVI announces a collaboration with Roche for the manufacture of a new medicine in development.
- ✓ Acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA). As part of the transaction, ROIS signed a 5-year Toll Manufacturing Agreement with BMS.
- ✓ Final Decision to award aid of €36.3 Mn for ROVI's LAISOLID project subsidised by the CDTI.



## Operating revenue €Mn



## Specialty pharma business €Mn



### Heparin franchise\*

36% of operating revenue

€189.8m

+7%

### Enoxaparin sales

€112.8m

+11%

- ✓ Sales of enoxaparin increased mainly to the increase in orders from international partners in 9M 2025.
- ✓ ROVI expects Q4 2025 to be the strongest quarter of the year in terms of sales.
- ✓ ROVI expects full year sales to increase by a mid-single-digit percentage in 2025 vs 2024.

### Bemiparin sales

€70.8m

-0.4%

- ✓ ROVI expects Q4 2025 to be the strongest quarter of the year in terms of sales.
- ✓ ROVI expects full year sales to increase by a low-single-digit percentage in 2025 vs 2024.

\* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins

### Other prescription-based pharmaceutical products

#### Neparvis®

€42.1m

+10%

#### Okedi®

€41.0m

+102%

- ✓ Risperidone ISM®, a LAI of risperidone for schizophrenia.
- ✓ Marketed in Europe, Australia & Taiwan.

## CDMO<sup>(1)</sup> business €Mn


Total  
€181.7m

-28%


<sup>(1)</sup>Contract Development and Manufacturing Organisation

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 36-40) of the press release on the financial results for the first nine months of 2025. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>


## Gross profit €Mn



## SG&A expenses €Mn



## EBITDA €Mn



## R&D expenses €Mn €24.7

+42%


| Product                                                                                                                                                                   | Potential Indication | Current Situation            | Key Milestones                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Okedi®<br>Risperidone, monthly                                                                                                                                            | <b>Schizophrenia</b> | Approved                     | Marketed in Europe, and in Australia & Taiwan                                                                                  |
| Letrozole ISM®,<br>annual                                                                                                                                                 | <b>Breast Cancer</b> | Clinical development on hold | Phase I: Superior oestrogen suppression vs Femara®                                                                             |
| Letrozole SIE <sup>(1)</sup> ,<br>quarterly                                                                                                                               | <b>Breast Cancer</b> | Completion of phase I        | Phase I: positive readout confirms superior estrogen suppression vs Femara® and allows progression to phase III clinical trial |
| Risperidone, quarterly                                                                                                                                                    | <b>Schizophrenia</b> | Completion of phase I        | Phase I: positive readout allows progression to phase III clinical trial                                                       |
| Concentrated on improving posology for already approved compounds, which benefits risk / reward profile<br>Multiple FDA / GMP approved facilities to support the platform |                      |                              |                                                                                                                                |

(1) Superior Inhibition of Estrogen

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 36-40) of the press release on the financial results for the first nine months of 2025. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>



## Net profit €Mn



(1) Calculated excluding R&D expenses in 9M 2025 and 9M 2024

## News flow

### SPECIALTY PHARMA

- ✓ Additional new products to be launched
- ✓ Granting by the competent local authorities of the marketing authorisation of an Enoxaparin biosimilar outside Europe

### CDMO

- ✓ Production progress of key manufacturing agreements
- ✓ ROIS Phoenix

### ISM® Technology Platform

- ✓ Marketing of Okedi® in Europe and rest of the world
- ✓ Phase III clinical trial of a new three-monthly formulation of letrozole (Letrozole SIE)
- ✓ Phase III clinical trial of risperidone for a 3-monthly injection